Melanocortin Peptide Agonists Show Promise for Treating Sexual Dysfunction in Both Men and Women Through Central Brain Pathways
Melanocortin receptor agonist peptides — melanotan I, melanotan II, and bremelanotide — work through central brain pathways to enhance sexual arousal and function in both men and women, representing a fundamentally different approach from drugs like Viagra.
Quick Facts
What This Study Found
Clinical development of three melanocortin receptor (MCR) agonist peptides has advanced understanding of how the melanocortin pathway regulates sexual function. Melanotan I, melanotan II, and bremelanotide have been studied for treating erectile dysfunction in males and sexual arousal and orgasmic disorders in females.
Unlike phosphodiesterase-5 inhibitors (e.g., sildenafil/Viagra) that act peripherally on nitric oxide/cyclic GMP signaling in genital smooth muscle, MCR agonists target central nervous system pathways involved in mediating arousal and orgasm. The available data support the role of melanocortin pathway activation in regulating both male and female sexual functions, warranting further clinical investigation.
Key Numbers
How They Did This
Narrative review summarizing basic research and clinical study results for melanocortin receptor agonist peptides (melanotan I, melanotan II, bremelanotide) in the treatment of male erectile dysfunction and female sexual arousal and orgasmic disorders.
Why This Research Matters
Sexual dysfunction affects millions of people, and current treatments have significant limitations. PDE5 inhibitors work for many men with ED but don't address desire or arousal, and no comparable options existed for women until recently. Melanocortin peptide agonists represent a fundamentally different therapeutic mechanism — targeting brain circuits that control sexual motivation and arousal rather than just genital blood flow. Bremelanotide was eventually FDA-approved in 2019 for female hypoactive sexual desire disorder, validating this peptide-based approach.
The Bigger Picture
This review captures an important chapter in peptide drug development: the translation of melanocortin biology into sexual medicine. The melanocortin system was originally studied for its role in pigmentation and appetite, but its involvement in sexual function opened an entirely new therapeutic application. Bremelanotide's eventual FDA approval (2019, as Vyleesi) validated this approach and remains one of the few centrally-acting sexual dysfunction treatments available. The broader melanocortin peptide field continues to expand into obesity, inflammatory disorders, and other conditions.
What This Study Doesn't Tell Us
The review was published in 2014 and does not include the final clinical trial results that led to bremelanotide's FDA approval in 2019. Melanotan I and II were associated with side effects including nausea and skin darkening (due to melanocyte stimulation) that complicated their clinical development. The central mechanism of action raises questions about potential CNS side effects with long-term use. The exact melanocortin receptor subtypes mediating sexual effects were not fully characterized at the time of this review.
Questions This Raises
- ?Can melanocortin receptor agonists be optimized to selectively enhance sexual function without causing skin pigmentation changes?
- ?Does long-term use of centrally-acting melanocortin peptides for sexual dysfunction carry risks for mood, appetite, or other brain functions?
- ?Could melanocortin agonists be combined with peripheral-acting drugs like PDE5 inhibitors for patients with both desire and arousal deficits?
Trust & Context
- Key Stat:
- 3 peptide drugs reviewed Melanotan I, melanotan II, and bremelanotide — melanocortin receptor agonist peptides developed for male and female sexual dysfunction through central brain pathways
- Evidence Grade:
- This is a narrative review summarizing basic research and clinical study results. It provides a useful overview of the field at a specific time point (2014) but does not present new data or conduct a systematic analysis.
- Study Age:
- Published in 2014, this review predates the FDA approval of bremelanotide (Vyleesi) in 2019 for female hypoactive sexual desire disorder. The review's conclusions were subsequently validated by the clinical development and approval process.
- Original Title:
- Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.
- Published In:
- Expert opinion on investigational drugs, 23(11), 1477-83 (2014)
- Database ID:
- RPEP-02565
Evidence Hierarchy
Frequently Asked Questions
How are melanocortin peptides different from Viagra for sexual dysfunction?
Viagra (sildenafil) works by increasing blood flow to the genitals — a purely physical mechanism. Melanocortin peptide agonists like bremelanotide work in the brain, activating pathways that regulate sexual desire and arousal. This means they can address lack of desire and arousal — not just blood flow — making them useful for conditions Viagra can't treat.
Is bremelanotide (Vyleesi) available now?
Yes — bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder in premenopausal women. It's administered as a self-injection before anticipated sexual activity. This review, published in 2014, discussed the peptide during its clinical development phase.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02565APA
Ückert, Stefan; Bannowsky, Andreas; Albrecht, Knut; Kuczyk, Markus A. (2014). Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.. Expert opinion on investigational drugs, 23(11), 1477-83. https://doi.org/10.1517/13543784.2014.934805
MLA
Ückert, Stefan, et al. "Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.." Expert opinion on investigational drugs, 2014. https://doi.org/10.1517/13543784.2014.934805
RethinkPeptides
RethinkPeptides Research Database. "Melanocortin receptor agonists in the treatment of male and ..." RPEP-02565. Retrieved from https://rethinkpeptides.com/research/uckert-2014-melanocortin-receptor-agonists-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.